GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Research & Development

VRAX (Virax Biolabs Group) Research & Development : $1.78 Mil (TTM As of Mar. 2025)


View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Virax Biolabs Group's Research & Development for the six months ended in Mar. 2025 was $1.05 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was $1.78 Mil.

Virax Biolabs Group Research & Development Historical Data

The historical data trend for Virax Biolabs Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Research & Development Chart

Virax Biolabs Group Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Research & Development
Get a 7-Day Free Trial 0.12 0.43 2.18 1.56 1.78

Virax Biolabs Group Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 2.08 0.61 0.96 0.73 1.05

Virax Biolabs Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virax Biolabs Group  (NAS:VRAX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Virax Biolabs Group Research & Development Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Research & Development
Comparable Companies
SXTP ZVSA PKTX SPRC JAGX PALI REVB NBY ADTX SONN VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH
Website
https://www.viraxbiolabs.com
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.